Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14281527 | 0.86 | TACR3 (0.58) | LMNAL3MBTL1 | |
| SCHEMBL10990332 | 0.81 | TACR3 (0.51) | — | |
| SCHEMBL13585802 | 0.79 | CYP3A4 (0.56) | SCN9AHTTL3MBTL1 | |
| SCHEMBL10749116 | 0.78 | SCN9A (0.57) | SCN9ALMNA | |
| SCHEMBL8069465 | 0.77 | SCN9A (0.81) | SCN9ALMNA | |
| SCHEMBL10986022 | 0.75 | SCN9A (0.76) | SCN9A | |
| SCHEMBL12903055 | 0.72 | MEN1 (0.73) | HTTRAB9AL3MBTL1 | |
| SCHEMBL8220491 | 0.71 | KDM4E (0.46) | LMNAHTTRAB9AL3MBTL1 | |
| Hydrochloric Acid SCHEMBL14843094 | 0.71 | CCKAR (0.42) | HSP90AB1RAB9A | |
| SCHEMBL20467410 | 0.70 | ALDH1A1 (0.81) | LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915267-B2 | Heterocyclic amide compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-29 | — | — | US | disclosed |
| US-20090137603-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137603-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | MMP2, MMP9, MMP1 | SCN9A 2076/4885LMNA 3074/4885HSP90AB1 2025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.